78.04
price up icon3.24%   2.45
after-market 시간 외 거래: 80.00 1.96 +2.51%
loading
전일 마감가:
$75.59
열려 있는:
$75.77
하루 거래량:
1.62M
Relative Volume:
0.87
시가총액:
$15.11B
수익:
$4.41B
순이익/손실:
$21.27M
주가수익비율:
243.88
EPS:
0.32
순현금흐름:
$288.81M
1주 성능:
+11.23%
1개월 성능:
+14.01%
6개월 성능:
+5.29%
1년 성능:
+21.05%
1일 변동 폭
Value
$75.48
$78.25
1주일 범위
Value
$71.00
$78.77
52주 변동 폭
Value
$53.56
$83.95

인사이트 코퍼레이션 Stock (INCY) Company Profile

Name
명칭
Incyte Corp
Name
전화
(302) 498-6700
Name
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
직원
2,617
Name
트위터
@Incyte
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
INCY's Discussions on Twitter

INCY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INCY
Incyte Corp
78.04 14.76B 4.41B 21.27M 288.81M 0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 118.67B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.54 59.23B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
419.56 52.67B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
690.32 41.24B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
304.30 32.36B 3.81B -644.79M -669.77M -6.24

인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-01 개시 Barclays Overweight
2025-06-16 업그레이드 Stifel Hold → Buy
2025-03-18 다운그레이드 Guggenheim Buy → Neutral
2025-03-18 다운그레이드 William Blair Outperform → Mkt Perform
2024-12-17 개시 UBS Neutral
2024-10-29 업그레이드 BofA Securities Neutral → Buy
2024-10-01 개시 Wolfe Research Outperform
2024-09-18 다운그레이드 Truist Buy → Hold
2024-07-02 다운그레이드 BMO Capital Markets Market Perform → Underperform
2024-05-23 개시 Deutsche Bank Hold
2024-04-23 개시 Cantor Fitzgerald Neutral
2024-02-23 개시 Jefferies Buy
2024-02-14 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 업그레이드 Leerink Partners Market Perform → Outperform
2023-12-04 업그레이드 Guggenheim Neutral → Buy
2023-11-21 다운그레이드 Goldman Buy → Neutral
2023-07-25 개시 Citigroup Buy
2023-05-04 다운그레이드 BofA Securities Buy → Neutral
2023-04-10 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-03-24 업그레이드 SVB Securities Underperform → Market Perform
2023-01-31 개시 Piper Sandler Overweight
2022-08-03 다운그레이드 Evercore ISI Outperform → In-line
2022-08-03 다운그레이드 Guggenheim Buy → Neutral
2022-07-28 개시 Wells Fargo Equal Weight
2022-02-09 다운그레이드 SVB Leerink Mkt Perform → Underperform
2022-01-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-19 개시 BMO Capital Markets Market Perform
2021-07-20 업그레이드 The Benchmark Company Hold → Buy
2021-02-10 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-01-07 개시 Truist Buy
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-06-16 개시 The Benchmark Company Hold
2020-05-06 다운그레이드 JP Morgan Overweight → Neutral
2020-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-24 재개 William Blair Outperform
2020-03-13 업그레이드 BofA/Merrill Neutral → Buy
2020-02-04 재개 BofA/Merrill Neutral
2020-01-03 재확인 BMO Capital Markets Market Perform
2020-01-03 다운그레이드 Mizuho Buy → Neutral
2020-01-02 다운그레이드 Guggenheim Buy → Neutral
2019-10-03 개시 Mizuho Buy
2019-09-12 개시 BMO Capital Markets Market Perform
2019-09-05 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 재개 Morgan Stanley Equal-Weight
2019-09-05 업그레이드 Oppenheimer Perform → Outperform
2019-05-21 개시 Credit Suisse Neutral
2019-05-03 다운그레이드 Barclays Overweight → Equal Weight
2019-04-11 개시 Stifel Hold
2019-04-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-01-24 업그레이드 William Blair Mkt Perform → Outperform
모두보기

인사이트 코퍼레이션 주식(INCY)의 최신 뉴스

pulisher
04:47 AM

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times

04:47 AM
pulisher
Aug 03, 2025

Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 01, 2025

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus

Aug 01, 2025
pulisher
Jul 30, 2025

Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte: Q2 Earnings Snapshot - Huron Daily Tribune

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Jul 30, 2025
pulisher
Jul 29, 2025

Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte rises on results beat, lifted Jakafi guidance - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Q2 Results Top Estimates - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte misses Q2 earnings estimates, raises Jakafi guidance - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Reports 2025 Second Quarter Financial Results - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Yahoo Finance

Jul 29, 2025

인사이트 코퍼레이션 (INCY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$37.88
price up icon 2.07%
$111.24
price up icon 2.35%
$29.32
price up icon 8.31%
$110.03
price up icon 2.51%
biotechnology ONC
$304.30
price up icon 1.77%
자본화:     |  볼륨(24시간):